HAVCR2 Specific NeutraTM Antibody Products
Product listBasic Information
Hepatitis A Virus Cellular Receptor 2 (HAVCR2), also known as TIM-3 and CD366, encodes a cell surface protein that interacts with ligands such as LGALS9, HMGB1, and phosphatidylserine. As a CD molecule and an immune checkpoint protein, it is expressed primarily in CD4+ Th cells, CD8+ Tc cells, and innate immune cells. By binding to ligands, HAVCR2 transmits the inhibitory signal in autoimmune and alloimmune responses.
Its Gene ID is 84868, UniProtKB ID is Q8TDQ0, and OMIM ID is 606652.
Function
Functions for HAVCR2 include:
- Inhibits Th17 cell responses.
- Promotes secretion of TNF-alpha.
- Promotes immunological tolerance.
- Promotes apoptotic cell conjugation and phagocytosis.
- Attenuates TCR-induced signaling and reduces IL-2 secretion.
- Inhibits Th1-mediated autoimmune and alloimmune responses.
Signal Pathway in T Cells
The binding of Bat-3 to the cytoplasmic tail of HAVCR2 (Tim-3), triggers the activation of T cells, which are then able to promote T-cell proliferation and survival. The ligation of HAVCR2, which displaces Bat-3 from the tail, downregulates TCR signaling and suppresses the proliferation and survival of T cells.
Fig.1 HAVCR2 (Tim-3) signaling in T cells.1
Drug Development
As an antibody target, HAVCR2 and its inhibitory signaling pathway have significant potential for next-generation cancer immunotherapy. Extensive data from clinical trials (Fig. 2) and preclinical studies have shown that blocking HAVCR2 is a promising way to improve antitumor immunity.
Table 1 List of anti-HAVCR2 antibodies in clinical trials.1
Antibody Validation
Anti-HAVCR2 Monoclonal Antibodies at Creative Biolabs are characterized by high specificity and strict quality control.
Fig. 2 V3S-0522-YC2244 was analyzed in SDS-PAGE.
Fig. 3 V3S-0622-YC2647 detected HAVCR2 in ELISA.
Fig. 4 The purity of V3S-0622-YC2647 was analyzed by SEC-HPLC.
REFERENCE
- Acharya, Nandini, Catherine Sabatos-Peyton, and Ana Carrizosa Anderson. "Tim-3 finds its place in the cancer immunotherapy landscape." Journal for immunotherapy of cancer 8.1 (2020).
